ALNY - Alnylam Pharmaceuticals, Inc.
About Alnylam Pharmaceuticals, Inc. (https://www.alnylam.com)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Yvonne L. Greenstreet | Chief Executive Officer & Director | 1963 | $4,991,720 USD |
| Pushkal Garg | Executive VP & Chief Research & Development Officer | 1968 | $1,862,800 USD |
| Jeffrey V. Poulton | Chief Financial Officer & Executive Vice President | 1968 | $1,697,100 USD |
| Tolga Tanguler | Executive Vice President & Chief Commercial Officer | 1973 | $1,501,320 USD |
| Kevin Joseph Fitzgerald | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development | 1969 | $1,225,300 USD |
| Bryan Andrew Supran | Chief Legal Officer | 1970 | $845,920 USD |
| Phillip A. Sharp | Co-Founder, Member of the Scientific Advisory Board | 1945 | $52,930 USD |
| Christine Regan Akinc | Chief Corporate Communications Officer | 1982 | – |
| Melissa McLaughlin | Chief Human Resources Officer | – | – |
| Muthiah Manoharan | Senior Vice President of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board | 1953 | – |
| Piyush Sharma | Chief Ethics & Compliance Officer | – | – |
| Timothy J. Maines | Chief Technical Operations & Quality Officer | – | – |